Sugi Predict

Sugi Predict / Compounds / SCHEMBL3872976

SCHEMBL3872976

SCHEMBL3872976

CC(C)(C)OC(=O)N1Cc2ccc(C=O)cc2C1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.67
▸ ESR2 Q92731 1/20 0.54
▸ NR1H2 P55055 2/20 0.53
▸ DDB1 Q16531 2/20 0.50
▸ CRBN Q96SW2 2/20 0.50
▸ MAPK1 P28482 1/20 0.44
▸ NAMPT P43490 4/20 0.43
▸ PIK3CA P42336 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ ROCK2 O75116 1/20 0.40
▸ ABHD6 Q9BV23 2/20 0.40
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30091900 1.00 HDAC1 (0.67) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL2222982 0.89 ESR2 (0.70) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL29590724 0.89 NR1H2 (0.69) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL31084557 0.89 ESR2 (0.70) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL14101204 0.89 NR1H2 (0.69) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL29835114 0.87 HDAC1 (0.66) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL3882492 0.87 HDAC1 (0.66) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL3871420 0.85 HDAC1 (0.63) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL30090244 0.85 HDAC1 (0.63) HDAC1ESR2NR1H2DDB1CRBN
SCHEMBL29090637 0.85 HDAC1 (0.63) HDAC1ESR2NR1H2DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2026-05-07 — — US disclosed
US-12517130-B2 Isoindoline derivatives which bind to an ATP binding site Neophore Limited (GB) 2026-01-06 — — US disclosed
EP-4651955-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2025-11-26 — — EP disclosed
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 — — EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 — — US disclosed
EP-4573096-A1 INHIBITORS OF MYELOPEROXIDASE Astrazeneca AB (SE) 2025-06-25 — — EP disclosed
CN-115397811-B Isoindoline derivatives binding to ATP binding sites 奈奥芬莱有限公司 2025-05-23 — — CN disclosed
CN-119894896-A Inhibitors of green peroxidase 阿斯利康(瑞典)有限公司 2025-04-25 — — CN disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed
US-20240299360-A1 ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) 2024-09-12 — — US disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 — — US disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 — — US disclosed
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES JOLIDON SYNESE 2009-08-13 — — US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 — — US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 — — US disclosed
US-7557114-B2 Heterocyclic-substituted phenyl methanones HOFFMAN-LA ROCHE INC. (US) 2009-07-07 — — US disclosed
EP-1848694-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F. Hoffmann-Roche AG (CH) 2007-10-31 — — EP disclosed
WO-2006082001-A1 HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 F.HOFFMANN-LA ROCHE AG (CH) 2006-08-10 — — WO disclosed
US-20060178381-A1 Heterocyclic-substituted phenyl methanones HOFFMANN-LA ROCHE INC. 2006-08-10 — — US disclosed
US-6200978-B1 FOR PREVENTING OR TREATING INFLAMMATORY DISEASES SUCH AS ARTHRITIS, PSORIASIS, ASTHMA, OR INFLAMMATORY BOWEL DISEASE, DISORDERS OF RESPIRATORY FUNCTION, GASTROINTESTINAL DISORDERS SUCH AS FUNCTIONAL BOWEL DISEASE, AS ANALGESICS PFIZER INC. 2001-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203665-A1 HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES CYP2B6, CYP2D6, CYP1A2 HDAC1 1995/4885ESR2 1665/4885NR1H2 542/4885
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HDAC1 372/4885ESR2 716/4885NR1H2 33/4885
US-20060178381-A1 Heterocyclic-substituted phenyl methanones CYP2B6, CYP2D6, CYP1A2 HDAC1 1995/4885ESR2 1665/4885NR1H2 542/4885
US-20240299360-A1 ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF ADAMTS5, ADAMTS4, ADAMTS1 HDAC1 1290/4885ESR2 4386/4885NR1H2 3855/4885
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 HDAC1 158/4885ESR2 1115/4885NR1H2 609/4885
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA HDAC1 325/4885ESR2 893/4885NR1H2 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.